BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $5 to $4.
BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $5 to $4.